{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:48:21Z","timestamp":1791823701183,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Research Topics of Hunan Provincial Health Commission","award":["20232585"],"award-info":[{"award-number":["20232585"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07135-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:47:27Z","timestamp":1784137647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral blood CD8\u2009+\u2009T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients"],"prefix":"10.1007","volume":"105","author":[{"given":"Fang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"20","key":"7135_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"4","key":"7135_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"22","key":"7135_CR3","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","volume":"23","author":"LH Sehn","year":"2005","unstructured":"Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O\u2019Reilly S, Spinelli JJ, Sutherland J et al (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23(22):5027\u20135033","journal-title":"J Clin Oncol"},{"issue":"14","key":"7135_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model","year":"1993","unstructured":"A predictive model (1993) for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994","journal-title":"N Engl J Med"},{"issue":"5","key":"7135_CR5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857\u20131861","journal-title":"Blood"},{"issue":"5","key":"7135_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690","journal-title":"Nat Med"},{"issue":"4","key":"7135_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298\u2013306","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"7135_CR8","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234(6):8509\u20138521","journal-title":"J Cell Physiol"},{"issue":"5795","key":"7135_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, Tosolini M, Camus M, Berger A, Wind P et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, NY) 313(5795):1960\u20131964","journal-title":"Science (New York, NY)"},{"issue":"25","key":"7135_CR10","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pag\u00e8s","year":"2005","unstructured":"Pag\u00e8s F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654\u20132666","journal-title":"N Engl J Med"},{"issue":"2","key":"7135_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2011.07.010","volume":"35","author":"N Zhang","year":"2011","unstructured":"Zhang N, Bevan MJ (2011) CD8(+) T cells: foot soldiers of the immune system. Immunity 35(2):161\u2013168","journal-title":"Immunity"},{"issue":"10","key":"7135_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"JA Trapani","year":"2002","unstructured":"Trapani JA, Smyth MJ (2002) Functional significance of the perforin\/granzyme cell death pathway. Nat Rev Immunol 2(10):735\u2013747","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"7135_CR13","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Martinez-Lostao","year":"2015","unstructured":"Martinez-Lostao L, Anel A, Pardo J (2015) How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 21(22):5047\u20135056","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7135_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","volume":"137","author":"D Behl","year":"2007","unstructured":"Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN et al (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 137(5):409\u2013415","journal-title":"Br J Haematol"},{"issue":"6","key":"7135_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1600-0609.2008.01129.x","volume":"81","author":"Y Oki","year":"2008","unstructured":"Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients\u2019 survival benefit from rituximab. Eur J Haematol 81(6):448\u2013453","journal-title":"Eur J Haematol"},{"issue":"9","key":"7135_CR16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE et al (2011) The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25(9):1502\u20131509","journal-title":"Leukemia"},{"issue":"4","key":"7135_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"28","key":"7135_CR18","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3460\u20133467","journal-title":"J Clin Oncol"},{"issue":"4","key":"7135_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2353\/jmoldx.2008.080023","volume":"10","author":"ML Gulley","year":"2008","unstructured":"Gulley ML, Tang W (2008) Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 10(4):279\u2013292","journal-title":"J Mol Diagn"},{"issue":"9","key":"7135_CR20","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/echo.13278","volume":"33","author":"V Schiano-Lomoriello","year":"2016","unstructured":"Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A, Della Pepa R, Picardi M, Catalano L, Trimarco B et al (2016) Longitudinal strain of left ventricular basal segments and E\/e\u2019 ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography (Mount Kisco, NY) 33(9):1335\u20131343","journal-title":"Echocardiography (Mount Kisco, NY)"},{"issue":"10","key":"7135_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70240","volume":"9","author":"M Picardi","year":"2025","unstructured":"Picardi M, Vincenzi A, Pugliese N, Giordano C, Prastaro M, Esposito R, Pane F (2025) Liposomal doxorubicin in place of doxorubicin hydrochloride to prevent anthracycline-induced cardiomyopathy in elderly patients with Hodgkin lymphoma. HemaSphere 9(10):e70240","journal-title":"HemaSphere"},{"issue":"13","key":"7135_CR22","first-page":"5132","volume":"61","author":"O Nakano","year":"2001","unstructured":"Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61(13):5132\u20135136","journal-title":"Cancer Res"},{"key":"7135_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051175","author":"Y Su","year":"2021","unstructured":"Su Y, Tsagkozis P, Papakonstantinou A, Tobin N, Gultekin O, Malmerfelt A, Ingelshed K, Neo S-Y, Lundquist J, Chaabane W et al (2021) CD11c-CD8 spatial cross presentation: a novel approach to link immune surveillance and patient survival in soft tissue sarcoma. Cancers. https:\/\/doi.org\/10.3390\/cancers13051175","journal-title":"Cancers"},{"key":"7135_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317706209","author":"J Xi","year":"2017","unstructured":"Xi J, Xu M, Song Z, Li H, Xu S, Wang C, Song H, Bai J (2017) Stimulatory role of interleukin 10 in CD8\u2009+\u2009T cells through STATs in gastric cancer. Tumour Biol. https:\/\/doi.org\/10.1177\/1010428317706209","journal-title":"Tumour Biol"},{"key":"7135_CR25","doi-asserted-by":"publisher","first-page":"9159","DOI":"10.1128\/JVI.00422-06","volume":"80","author":"S Fuse","year":"2006","unstructured":"Fuse S, Obar J, Bellfy S, Leung E, Zhang W, Usherwood E (2006) CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol 80:9159\u20139170","journal-title":"J Virol"},{"key":"7135_CR26","doi-asserted-by":"crossref","unstructured":"Zheng S, Jiajia, Li J, Pang X, Mingfu, Zhiping, Cui W (2023) Lower PTEN may be associated with CD8\u2009+\u2009T cell exhaustion in diffuse large B-cell lymphoma. Hum Immunol","DOI":"10.21203\/rs.3.rs-2950216\/v1"},{"key":"7135_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05002-3","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Yang Y, Chen K, Zhang Q, Huang Y, Jian S (2024) Diffuse large B-cell lymphoma: the significance of CD8\u2009+\u2009tumor-infiltrating lymphocytes exhaustion mediated by TIM3\/Galectin-9 pathway. J Transl Med. https:\/\/doi.org\/10.1186\/s12967-024-05002-3","journal-title":"J Transl Med"},{"issue":"Suppl","key":"7135_CR28","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara H et al (2015) Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 35(Suppl):S185-s198","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"7135_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW (2022) Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol 15(1):61","journal-title":"J Hematol Oncol"},{"key":"7135_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1526772","author":"L Zhang","year":"2025","unstructured":"Zhang L, Cheng R, Fan Z, Liu Y, Huang J, Peng J (2025) CD73\u2009+\u2009CD8+ T cells define a subset with anti-tumor potential in DLBCL patients. Front Med. https:\/\/doi.org\/10.3389\/fmed.2025.1526772","journal-title":"Front Med"},{"key":"7135_CR31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178327","author":"H-Y Wang","year":"2023","unstructured":"Wang H-Y, Yang F-C, Yang C-F, Tsai C, Ko P, Liu Y-C, Chen N-J (2023) Ratio of circulating CD8\u2009+\u2009T lymphocytes to M-MDSCs (CD8MMR): a novel prognostic predictor for treatment-na\u00efve DLBCL patients. Blood. https:\/\/doi.org\/10.1182\/blood-2023-178327","journal-title":"Blood"},{"issue":"25","key":"7135_CR32","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1182\/blood.2023020780","volume":"144","author":"AJ Davies","year":"2024","unstructured":"Davies AJ (2024) The high-grade B-cell lymphomas: double hit and more. Blood 144(25):2583\u20132592","journal-title":"Blood"},{"issue":"20","key":"7135_CR33","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","volume":"129","author":"D Ennishi","year":"2017","unstructured":"Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R et al (2017) Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129(20):2760\u20132770","journal-title":"Blood"},{"issue":"15","key":"7135_CR34","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378(15):1396\u20131407","journal-title":"N Engl J Med"},{"issue":"6","key":"7135_CR35","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N et al (2021) Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov 11(6):1468\u20131489","journal-title":"Cancer Discov"},{"issue":"1","key":"7135_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10657-0","volume":"23","author":"T Lei","year":"2023","unstructured":"Lei T, Wu G, Xu Y, Zhuang W, Lu J, Han S, Zhuang Y, Dong X, Yang H (2023) Peripheral immune cell profiling of double-hit lymphoma by mass cytometry. BMC Cancer 23(1):184","journal-title":"BMC Cancer"},{"issue":"5","key":"7135_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cjp2.283","volume":"8","author":"CT Yuan","year":"2022","unstructured":"Yuan CT, Chuang SS, Cheng PY, Chang K, Wang H, Tsai JH, Liau JY, Chou WC (2022) Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit\/triple-hit genotype and survival in diffuse large B-cell lymphoma. The journal of pathology Clinical research 8(5):436\u2013447","journal-title":"The journal of pathology Clinical research"},{"issue":"5","key":"7135_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.70005","volume":"41","author":"XZ Guo","year":"2025","unstructured":"Guo XZ, Guo YF, Wu SX (2025) Expression and clinical significance of CXCR5 and LAG-3 on peripheral blood CD8 (+) T cells in patients with diffuse large B-cell lymphoma. Kaohsiung J Med Sci 41(5):e70005","journal-title":"Kaohsiung J Med Sci"},{"issue":"5","key":"7135_CR39","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1111\/ajco.13730","volume":"18","author":"N Shokrgozar","year":"2022","unstructured":"Shokrgozar N, Dehghani M, Golmoghaddam H, Moghadam M, Rezaei N, Moayed V, Arandi N (2022) The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: association with disease status and clinical outcomes. Asia Pac J Clin Oncol 18(5):e388\u2013e397","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"7135_CR40","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.32604\/or.2025.063484","volume":"33","author":"W Chen","year":"2025","unstructured":"Chen W, Zhou X, Li H, Yang Y, Lu L, Zhu C, Fang R, Chu X, Zhou S, Sun Q (2025) Rare primary diffuse large B-cell lymphoma confined to bone marrow: features and prognosis. Oncol Res 33(8):2123\u20132139","journal-title":"Oncol Res"},{"issue":"1","key":"7135_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2478\/raon-2024-0004","volume":"58","author":"A Doma","year":"2024","unstructured":"Doma A, Zevnik K, Studen A, Prevodnik VK, Gasljevic G, Novakovic BJ (2024) Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre (18)F-FDG PET\/CT and bone marrow biopsy evaluation study. Radiol Oncol 58(1):15\u201322","journal-title":"Radiol Oncol"},{"issue":"1","key":"7135_CR42","first-page":"2621541","volume":"31","author":"L Qiaochu","year":"2026","unstructured":"Qiaochu L, Lianming L, Jianzhen S, XiaoFeng L, Haiying F, Tingbo L (2026) Characteristics and prognosis of Epstein Barr virus-positive diffuse large B-cell lymphoma: a retrospective, single-center study. Hematol (Amsterdam Netherlands) 31(1):2621541","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"3","key":"7135_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12185-018-2466-7","volume":"108","author":"Y Shi","year":"2018","unstructured":"Shi Y, Deng L, Song Y, Lin D, Lai Y, Zhou L, Yang L, Li X (2018) CD3+\/CD8\u2009+\u2009T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. Int J Hematol 108(3):254\u2013266","journal-title":"Int J Hematol"},{"key":"7135_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13155","author":"A Hashmi","year":"2021","unstructured":"Hashmi A, Iftikhar S, Nargus G, Ahmed O, Asghar I, Shirazi UA, Afzal A, Irfan M, Ali J (2021) Double-expressor phenotype (BCL-2\/c-MYC co-expression) of diffuse large B-cell lymphoma and its clinicopathological correlation. Cureus. https:\/\/doi.org\/10.7759\/cureus.13155","journal-title":"Cureus"},{"key":"7135_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133369","author":"J Hwang","year":"2021","unstructured":"Hwang J, Suh C, Kim K, Kim H, Kim AI, Craig JW, Chen KX, Roberson J, Guenette JP, Huang RY (2021) The incidence and treatment response of double expression of MYC and BCL2 in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers13133369","journal-title":"Cancers"},{"issue":"4","key":"7135_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"35","key":"7135_CR47","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO-25-00925","volume":"43","author":"F Morschhauser","year":"2025","unstructured":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M, Lenz G, Sharman JP, Herbaux C, Burke JM et al (2025) Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol 43(35):3698\u20133705","journal-title":"J Clin Oncol"},{"issue":"12","key":"7135_CR48","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/dc.21127","volume":"37","author":"I Cozzolino","year":"2009","unstructured":"Cozzolino I, Nappa S, Picardi M, De Renzo A, Troncone G, Palombini L, Zeppa P (2009) Clonal B-cell population in a reactive lymph node in acquired immunodeficiency syndrome. Diagn Cytopathol 37(12):910\u2013914","journal-title":"Diagn Cytopathol"},{"issue":"4","key":"7135_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000448389","volume":"60","author":"I Cozzolino","year":"2016","unstructured":"Cozzolino I, Rocco M, Villani G, Picardi M (2016) Lymph node fine-needle cytology of non-Hodgkin lymphoma: diagnosis and classification by flow cytometry. Acta Cytol 60(4):302\u2013314","journal-title":"Acta Cytol"},{"key":"7135_CR50","doi-asserted-by":"publisher","first-page":"b605","DOI":"10.1136\/bmj.b605","volume":"338","author":"DG Altman","year":"2009","unstructured":"Altman DG, Vergouwe Y, Royston P, Moons KG (2009) Prognosis and prognostic research: validating a prognostic model. BMJ (Clinical Res ed) 338:b605","journal-title":"BMJ (Clinical Res ed)"},{"issue":"11","key":"7135_CR51","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","volume":"14","author":"DE Speiser","year":"2014","unstructured":"Speiser DE, Utzschneider DT, Oberle SG, M\u00fcnz C, Romero P, Zehn D (2014) T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 14(11):768\u2013774","journal-title":"Nat Rev Immunol"},{"issue":"27","key":"7135_CR52","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin oncology: official J Am Soc Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"6230","key":"7135_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69\u201374","journal-title":"Science"},{"issue":"31","key":"7135_CR54","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733\u20133739","journal-title":"J Clin Oncol"},{"issue":"328","key":"7135_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv324","journal-title":"Sci Transl Med"},{"issue":"8","key":"7135_CR56","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938\u2013945","journal-title":"Nat Med"},{"issue":"3","key":"7135_CR57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/ejh.13274","volume":"103","author":"C Keane","year":"2019","unstructured":"Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, Gill A, Stevenson W, Talaulikar D, Gould C et al (2019) The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. Eur J Haematol 103(3):200\u2013207","journal-title":"Eur J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07135-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:03:14Z","timestamp":1791820994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7135"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07135-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of the Central Hospital of Xiangtan [Approval NO: 2017-05-10], and followed the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"449"}}